Skip to main content
Erschienen in: Wiener Medizinische Wochenschrift 21-22/2014

01.11.2014 | main topic

A short update on cancer chemoresistance

verfasst von: Gerhard Hamilton, Barbara Rath

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 21-22/2014

Einloggen, um Zugang zu erhalten

Summary

Chemotherapeutic interventions in cancer patients are limited by the appearance of chemoresistance. For instance, advanced lung and ovarian cancer patients relapse invariably after few cycles of platinum-based chemotherapy. Disseminated tumors are characterized by genetic instability/heterogeneity, thus containing or generating a repertoire of resistant subpopulations. At the cellular level, altered drug uptake, efflux, and metabolization, as well as modifications of drug targets, increased repair, and decreased cell death complement the limited perfusion and adverse hypoxic/acidic extracellular conditions at the tumor level in retaining cancer cell viability. Similarly, targeted therapy is rendered ineffective by mutations of the specific target protein within a few months or years of administration. Assessment of the expression profiles of resistant tumor cells revealed extensive changes in numerous pathways affecting hundreds of genes. Therefore, reversal of drug resistance will require individual profiles of drug resistance mediators and the combination of several specific drugs, targeting critical components to provide new therapeutic options.
Literatur
1.
Zurück zum Zitat Wilson TR, Longley DB, Johnston PG. Chemoresistance in solid tumours. Ann Oncol. 2006;17:315–24.CrossRef Wilson TR, Longley DB, Johnston PG. Chemoresistance in solid tumours. Ann Oncol. 2006;17:315–24.CrossRef
2.
Zurück zum Zitat Meads MB, Gatenby RA, Dalton WS. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer. 2009;9:665–74.PubMedCrossRef Meads MB, Gatenby RA, Dalton WS. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer. 2009;9:665–74.PubMedCrossRef
5.
Zurück zum Zitat Pinedo HM, Giaccone G. Drug resistance in the treatment of cancer. Cambridge: Cambridge University Press; 2007. Pinedo HM, Giaccone G. Drug resistance in the treatment of cancer. Cambridge: Cambridge University Press; 2007.
6.
Zurück zum Zitat Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014. pii: S0140-6736(13)62146-7. Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014. pii: S0140-6736(13)62146-7.
7.
Zurück zum Zitat Rosell R, Cecere F, Santarpia M, Reguart N, Taron M. Predicting the outcome of chemotherapy for lung cancer. Curr Opin Pharmacol. 2006;6:323–31.PubMedCrossRef Rosell R, Cecere F, Santarpia M, Reguart N, Taron M. Predicting the outcome of chemotherapy for lung cancer. Curr Opin Pharmacol. 2006;6:323–31.PubMedCrossRef
8.
Zurück zum Zitat Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13:714–26.PubMedCrossRef Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13:714–26.PubMedCrossRef
9.
Zurück zum Zitat O’Connor ML, Xiang D, Shigdar S, Macdonald J, Li Y, Wang T, Pu C, Wang Z, Qiao L, Duan W. Cancer stem cells: a contentious hypothesis now moving forward. Cancer Lett. 2014;344:180–7.PubMedCrossRef O’Connor ML, Xiang D, Shigdar S, Macdonald J, Li Y, Wang T, Pu C, Wang Z, Qiao L, Duan W. Cancer stem cells: a contentious hypothesis now moving forward. Cancer Lett. 2014;344:180–7.PubMedCrossRef
10.
11.
Zurück zum Zitat Ullah MF. Cancer multidrug resistance (MDR): a major impediment to effective chemotherapy. Asian Pac J Cancer Prev. 2008;9:1–6.PubMed Ullah MF. Cancer multidrug resistance (MDR): a major impediment to effective chemotherapy. Asian Pac J Cancer Prev. 2008;9:1–6.PubMed
12.
Zurück zum Zitat Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia. 2001;15:875–90.PubMedCrossRef Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia. 2001;15:875–90.PubMedCrossRef
13.
Zurück zum Zitat Damaraju VL, Damaraju S, Young JD, Baldwin SA, Mackey J, Sawyer MB, et al. Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene. 2003;22:7524–36.PubMedCrossRef Damaraju VL, Damaraju S, Young JD, Baldwin SA, Mackey J, Sawyer MB, et al. Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene. 2003;22:7524–36.PubMedCrossRef
14.
Zurück zum Zitat Longo-Sorbello GS, Bertino JR. Current understanding of methotrexate pharmacology and efficacy in acute leukemias. Use of newer antifolates in clinical trials. Haematologica. 2001;86:121–7.PubMed Longo-Sorbello GS, Bertino JR. Current understanding of methotrexate pharmacology and efficacy in acute leukemias. Use of newer antifolates in clinical trials. Haematologica. 2001;86:121–7.PubMed
15.
Zurück zum Zitat Nooter K, Stoter G. Molecular mechanisms of multidrug resistance in cancer chemotherapy. Pathol Res Pract. 1996;192:768–80.PubMedCrossRef Nooter K, Stoter G. Molecular mechanisms of multidrug resistance in cancer chemotherapy. Pathol Res Pract. 1996;192:768–80.PubMedCrossRef
16.
Zurück zum Zitat Nobili S, Landini I, Mazzei T, Mini E. Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression. Med Res Rev. 2012;32:1220–62.PubMedCrossRef Nobili S, Landini I, Mazzei T, Mini E. Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression. Med Res Rev. 2012;32:1220–62.PubMedCrossRef
17.
Zurück zum Zitat Jedlitschky G, Leier I, Buchholz U, Barnouin K, Kurz G, Keppler D. Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res. 1996;56:988–94.PubMed Jedlitschky G, Leier I, Buchholz U, Barnouin K, Kurz G, Keppler D. Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res. 1996;56:988–94.PubMed
18.
Zurück zum Zitat Konig J, Nies AT, Cui Y, Leier I, Keppler D. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim Biophys Acta. 1999;1461:377–94.PubMedCrossRef Konig J, Nies AT, Cui Y, Leier I, Keppler D. Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim Biophys Acta. 1999;1461:377–94.PubMedCrossRef
19.
Zurück zum Zitat Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst. 2000;92:1295–302.PubMedCrossRef Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst. 2000;92:1295–302.PubMedCrossRef
20.
Zurück zum Zitat Jäger W, Gehring E, Hagenauer B, Aust S, Senderowicz A, Thalhammer T. The role of hepatic Mrp2 in the interaction of flavopiridol and bilirubin: impact on therapy. Int J Clin Pharmacol Ther. 2003;41:610–1.PubMedCrossRef Jäger W, Gehring E, Hagenauer B, Aust S, Senderowicz A, Thalhammer T. The role of hepatic Mrp2 in the interaction of flavopiridol and bilirubin: impact on therapy. Int J Clin Pharmacol Ther. 2003;41:610–1.PubMedCrossRef
21.
Zurück zum Zitat Haberl I, Swatonek H, Schaufler K, Ulsperger E, Wenzl E, Theyer G, Hamilton G, Thalhammer T. P-glycoprotein-mediated multidrug resistance is modulated by pretreatment with chemosensitizers in HCT-8 carcinoma cells in vitro. Int J Oncol. 1998;12:1137–42.PubMed Haberl I, Swatonek H, Schaufler K, Ulsperger E, Wenzl E, Theyer G, Hamilton G, Thalhammer T. P-glycoprotein-mediated multidrug resistance is modulated by pretreatment with chemosensitizers in HCT-8 carcinoma cells in vitro. Int J Oncol. 1998;12:1137–42.PubMed
22.
Zurück zum Zitat Binkhathlan Z, Lavasanifar A. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives. Curr Cancer Drug Targets. 2013;13:326–46.PubMedCrossRef Binkhathlan Z, Lavasanifar A. P-glycoprotein inhibition as a therapeutic approach for overcoming multidrug resistance in cancer: current status and future perspectives. Curr Cancer Drug Targets. 2013;13:326–46.PubMedCrossRef
23.
Zurück zum Zitat Svoboda M, Riha J, Wlcek K, Jaeger W, Thalhammer T. Organic anion transporting polypeptides (OATPs): regulation of expression and function. Curr Drug Metab. 2011;12:139–53.PubMedCrossRef Svoboda M, Riha J, Wlcek K, Jaeger W, Thalhammer T. Organic anion transporting polypeptides (OATPs): regulation of expression and function. Curr Drug Metab. 2011;12:139–53.PubMedCrossRef
24.
Zurück zum Zitat Buxhofer-Ausch V, Secky L, Wlcek K, Svoboda M, Kounnis V, Briasoulis E, Tzakos AG, Jaeger W, Thalhammer T. Tumor-specific expression of organic anion-transporting polypeptides: transporters as novel targets for cancer therapy. J Drug Deliv. 2013;2013:863539.PubMedCentralPubMedCrossRef Buxhofer-Ausch V, Secky L, Wlcek K, Svoboda M, Kounnis V, Briasoulis E, Tzakos AG, Jaeger W, Thalhammer T. Tumor-specific expression of organic anion-transporting polypeptides: transporters as novel targets for cancer therapy. J Drug Deliv. 2013;2013:863539.PubMedCentralPubMedCrossRef
25.
Zurück zum Zitat Svoboda M, Wlcek K, Taferner B, Hering S, Stieger B, Tong D, Zeillinger R, Thalhammer T, Jäger W. Expression of organic anion-transporting polypeptides 1B1 and 1B3 in ovarian cancer cells: relevance for paclitaxel transport. Biomed Pharmacother. 2011;65:417–26.PubMedCrossRef Svoboda M, Wlcek K, Taferner B, Hering S, Stieger B, Tong D, Zeillinger R, Thalhammer T, Jäger W. Expression of organic anion-transporting polypeptides 1B1 and 1B3 in ovarian cancer cells: relevance for paclitaxel transport. Biomed Pharmacother. 2011;65:417–26.PubMedCrossRef
26.
Zurück zum Zitat Obaidat A, Roth M, Hagenbuch B. The expression and function of organic anion transporting polypeptides in normal tissues and in cancer. Annu Rev Pharmacol Toxicol. 2012;52:135–51.PubMedCentralPubMedCrossRef Obaidat A, Roth M, Hagenbuch B. The expression and function of organic anion transporting polypeptides in normal tissues and in cancer. Annu Rev Pharmacol Toxicol. 2012;52:135–51.PubMedCentralPubMedCrossRef
27.
Zurück zum Zitat Sampath D, Cortes J, Estrov Z, Du M, Shi Z, Andreeff M, et al. Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood. 2006;107:2517–24.PubMedCentralPubMedCrossRef Sampath D, Cortes J, Estrov Z, Du M, Shi Z, Andreeff M, et al. Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood. 2006;107:2517–24.PubMedCentralPubMedCrossRef
28.
Zurück zum Zitat Xu Y, Villalona-Calero MA. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol. 2002;13:1841–51.PubMedCrossRef Xu Y, Villalona-Calero MA. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol. 2002;13:1841–51.PubMedCrossRef
29.
Zurück zum Zitat Bardenheuer W, Lehmberg K, Rattmann I, Brueckner A, Schneider A, Sorg UR, et al. Resistance to cytarabine and gemcitabine and in vitro selection of transduced cells after retroviral expression of cytidine deaminase in human hematopoietic progenitor cells. Leukemia. 2005;19:2281–8.PubMedCrossRef Bardenheuer W, Lehmberg K, Rattmann I, Brueckner A, Schneider A, Sorg UR, et al. Resistance to cytarabine and gemcitabine and in vitro selection of transduced cells after retroviral expression of cytidine deaminase in human hematopoietic progenitor cells. Leukemia. 2005;19:2281–8.PubMedCrossRef
30.
Zurück zum Zitat Platzer P, Thalhammer T, Hamilton G, Ulsperger E, Rosenberg E, Wissiack R, Jäger W. Metabolism of camptothecin, a potent topoisomerase I inhibitor, in the isolated perfused rat liver. Cancer Chemother Pharmacol. 2000;45:50–4.PubMedCrossRef Platzer P, Thalhammer T, Hamilton G, Ulsperger E, Rosenberg E, Wissiack R, Jäger W. Metabolism of camptothecin, a potent topoisomerase I inhibitor, in the isolated perfused rat liver. Cancer Chemother Pharmacol. 2000;45:50–4.PubMedCrossRef
31.
Zurück zum Zitat Meijer C, Mulder NH, Timmer-Bosscha H, Sluiter WJ, Meersma GJ, De Vries EG. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res. 1992;52:6885–9.PubMed Meijer C, Mulder NH, Timmer-Bosscha H, Sluiter WJ, Meersma GJ, De Vries EG. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res. 1992;52:6885–9.PubMed
32.
Zurück zum Zitat Miksits M, Wlcek K, Svoboda M, Kunert O, Haslinger E, Thalhammer T, Szekeres T, Jäger W. Antitumor activity of resveratrol and its sulfated metabolites against human breast cancer cells. Planta Med. 2009;75:1227–30.PubMedCrossRef Miksits M, Wlcek K, Svoboda M, Kunert O, Haslinger E, Thalhammer T, Szekeres T, Jäger W. Antitumor activity of resveratrol and its sulfated metabolites against human breast cancer cells. Planta Med. 2009;75:1227–30.PubMedCrossRef
33.
Zurück zum Zitat Aust S, Obrist P, Klimpfinger M, Tucek G, Jäger W, Thalhammer T. Altered expression of the hormone- and xenobiotic-metabolizing sulfotransferase enzymes 1A2 and 1C1 in malignant breast tissue. Int J Oncol. 2005;26:1079–85.PubMed Aust S, Obrist P, Klimpfinger M, Tucek G, Jäger W, Thalhammer T. Altered expression of the hormone- and xenobiotic-metabolizing sulfotransferase enzymes 1A2 and 1C1 in malignant breast tissue. Int J Oncol. 2005;26:1079–85.PubMed
34.
Zurück zum Zitat Kelley SL, Basu A, Teicher BA, Hacker MP, Hamer DH, Lazo JS. Overexpression of metallothionein confers resistance to anticancer drugs. Science. 1988;241:1813–5.PubMedCrossRef Kelley SL, Basu A, Teicher BA, Hacker MP, Hamer DH, Lazo JS. Overexpression of metallothionein confers resistance to anticancer drugs. Science. 1988;241:1813–5.PubMedCrossRef
35.
Zurück zum Zitat Xu Y, Villalona-Calero MA. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol. 2002;13:1841–51.PubMedCrossRef Xu Y, Villalona-Calero MA. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann Oncol. 2002;13:1841–51.PubMedCrossRef
36.
Zurück zum Zitat Olszewski U, Liedauer R, Ausch C, Thalhammer T, Hamilton G. Overexpression of CYP3A4 in a COLO 205 colon cancer stem cell model in vitro. Cancers (Basel). 2011;3:1467–79.CrossRef Olszewski U, Liedauer R, Ausch C, Thalhammer T, Hamilton G. Overexpression of CYP3A4 in a COLO 205 colon cancer stem cell model in vitro. Cancers (Basel). 2011;3:1467–79.CrossRef
37.
Zurück zum Zitat Weinstein IB. Cancer. Addiction to oncogenes—the Achilles heal of cancer. Science. 2002;297:63–4.PubMedCrossRef Weinstein IB. Cancer. Addiction to oncogenes—the Achilles heal of cancer. Science. 2002;297:63–4.PubMedCrossRef
38.
Zurück zum Zitat Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423–32.PubMedCrossRef Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423–32.PubMedCrossRef
39.
Zurück zum Zitat Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–39.PubMedCrossRef Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129–39.PubMedCrossRef
40.
Zurück zum Zitat Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123–32.PubMedCrossRef Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123–32.PubMedCrossRef
41.
Zurück zum Zitat Hofmann WK, Komor M, Wassmann B, Jones LC, Gschaidmeier H, Hoelzer D, et al. Presence of the BCR–ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. Blood. 2003;102:659–61.PubMedCrossRef Hofmann WK, Komor M, Wassmann B, Jones LC, Gschaidmeier H, Hoelzer D, et al. Presence of the BCR–ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia. Blood. 2003;102:659–61.PubMedCrossRef
42.
Zurück zum Zitat Inukai M, Toyooka S, Ito S, Asano H, Ichihara S, Soh J, et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res. 2006;66:7854–8.PubMedCrossRef Inukai M, Toyooka S, Ito S, Asano H, Ichihara S, Soh J, et al. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res. 2006;66:7854–8.PubMedCrossRef
43.
Zurück zum Zitat Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR–ABL gene mutation or amplification. Science. 2001;293:876–80.PubMedCrossRef Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR–ABL gene mutation or amplification. Science. 2001;293:876–80.PubMedCrossRef
44.
Zurück zum Zitat Blencke S, Ullrich A, Daub H. Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors. J Biol Chem. 2003;278:15435–40.PubMedCrossRef Blencke S, Ullrich A, Daub H. Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors. J Biol Chem. 2003;278:15435–40.PubMedCrossRef
45.
Zurück zum Zitat le Coutre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, Cabrita G, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood. 2000;95:1758–66.PubMed le Coutre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, Cabrita G, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood. 2000;95:1758–66.PubMed
46.
47.
Zurück zum Zitat Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913–7.PubMedCrossRef Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913–7.PubMedCrossRef
49.
Zurück zum Zitat Fodale V, Pierobon M, Liotta L, Petricoin E. Mechanism of cell adaptation: when and how do cancer cells develop chemoresistance? Cancer J. 2011;17:89–95.PubMedCrossRef Fodale V, Pierobon M, Liotta L, Petricoin E. Mechanism of cell adaptation: when and how do cancer cells develop chemoresistance? Cancer J. 2011;17:89–95.PubMedCrossRef
50.
Zurück zum Zitat Thalhammer T, Kieffer LJ, Jiang T, Handschumacher RE. Isolation and partial characterization of membrane-associated cyclophilin and a related 22-kDa glycoprotein. Eur J Biochem. 1992;206:31–7.PubMedCrossRef Thalhammer T, Kieffer LJ, Jiang T, Handschumacher RE. Isolation and partial characterization of membrane-associated cyclophilin and a related 22-kDa glycoprotein. Eur J Biochem. 1992;206:31–7.PubMedCrossRef
51.
Zurück zum Zitat Hamilton G. Cyclophilin A as a target of Cisplatin chemosensitizers. Curr Cancer Drug Targets. 2014;14:46–58.PubMedCrossRef Hamilton G. Cyclophilin A as a target of Cisplatin chemosensitizers. Curr Cancer Drug Targets. 2014;14:46–58.PubMedCrossRef
52.
53.
54.
Zurück zum Zitat Lu HP, Chao CC. Cancer cells acquire resistance to anticancer drugs: an update. Biomed J. 2012;35:464–72.PubMedCrossRef Lu HP, Chao CC. Cancer cells acquire resistance to anticancer drugs: an update. Biomed J. 2012;35:464–72.PubMedCrossRef
55.
Zurück zum Zitat Hamilton G, Olszewski U. Chemotherapy-induced enrichment of cancer stem cells in lung cancer. J Bioanal Biomed. 2013;S9:003. Hamilton G, Olszewski U. Chemotherapy-induced enrichment of cancer stem cells in lung cancer. J Bioanal Biomed. 2013;S9:003.
56.
Zurück zum Zitat Castells M, Thibault B, Delord JP, Couderc B. Implication of tumor microenvironment in chemoresistance: tumor-associated stromal cells protect tumor cells from cell death. Int J Mol Sci. 2012;13:9545–71.PubMedCentralPubMedCrossRef Castells M, Thibault B, Delord JP, Couderc B. Implication of tumor microenvironment in chemoresistance: tumor-associated stromal cells protect tumor cells from cell death. Int J Mol Sci. 2012;13:9545–71.PubMedCentralPubMedCrossRef
Metadaten
Titel
A short update on cancer chemoresistance
verfasst von
Gerhard Hamilton
Barbara Rath
Publikationsdatum
01.11.2014
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 21-22/2014
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-014-0311-z

Weitere Artikel der Ausgabe 21-22/2014

Wiener Medizinische Wochenschrift 21-22/2014 Zur Ausgabe